Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the expansion of its COMET™ solution portfolio with the addition of ...
Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...
Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life ...
Shares of Bio-Techne Corp. TECH rose 1.01% to $52.00 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.15% to 6,581.00 and ...
Bio-Techne (TECH) is back in focus after institutional investors such as Jefferies Financial Group and Madison Investments ...
Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...
Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...
Bio-Techne TECH reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, which surpassed the Zacks Consensus Estimate by 6%. The bottom line improved from the year-ago figure ...
The collaboration between Leica Biosystems and Bio-Techne expands access to advanced RNA ISH technology for clinical ...
RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results